More Evidence for SGLT2 Inhibitors in Heart Failure

John Jarcho comments on the findings of the EMPEROR-Reduced trial, which assesses the potential benefit of empagliflozin in patients with heart failure and a reduced EF. He notes that the findings substantially strengthen the rationale for the use of SGLT2 inhibitors in such patients.